Results 151 to 160 of about 122,656 (259)

The m.14484T>C MT‐ND6 Mutation Presenting with a Hereditary Spastic‐Paraparesis Phenotype

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Gabriel Amorelli   +4 more
wiley   +1 more source

Automated Magnetic Resonance Volumetry to Measure Multiple System Atrophy Disease Progression in Clinical Trials

open access: yesMovement Disorders, EarlyView.
Abstract Background Recent studies have reported longitudinal brain atrophy in multiple system atrophy (MSA) in relatively small patient cohorts. Objective To compare longitudinal regional brain volume and clinical changes as endpoint measures for MSA clinical trials.
Andrea Quattrone   +62 more
wiley   +1 more source

Superior colliculus, midbrain

open access: yes, 1997
Superior colliculus, midbrain. Superior colliculus, pineal gland, medial geniculate, III N. Transverse plane.

core  

Neuropsychiatric‐Led Presentation of Late‐Onset Parkin‐Related Parkinson's Disease

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Sarah Fullam   +4 more
wiley   +1 more source

Navigating the Complexity: A Comprehensive Review of GSK‐3 Inhibition in Regenerative Medicine

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Glycogen synthase kinase‐3 (GSK‐3) is a central regulator of numerous cellular signaling pathways, with critical roles in metabolism, proliferation, differentiation, and tissue regeneration. This review explores the multifaceted effects of pharmacological GSK‐3 inhibition across multiple body districts, focusing on its highly context‐dependent
Davide Schiroli   +5 more
wiley   +1 more source

Tentorial notch with midbrain

open access: yes, 1997
Tentorial notch with midbrain. Ventral view of tentorium cerebelli in situ.

core  

Opsoclonus‐Myoclonus‐Ataxia Revealing Underlying Neuromyelitis Optica Spectrum Disorder

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Ana Silvia Sobreira Lima Verde   +6 more
wiley   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy